A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elesclomol (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacokinetics
Sponsors Synta Pharmaceuticals

Most Recent Events

31 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
31 Jan 2014 Planned End Date changed from 1 Sep 2012 to 1 Aug 2014 according to ClinicalTrials.gov record.
08 Feb 2011 The first patient has been treated, according to a Synta Pharmaceuticals media release

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight